Search | Clinical Trials Finder

Conditions: Coronary Artery Stenosis
Interventions: Not listed
Lead sponsor: Matthias Friedrich; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Angiography
Interventions: Endovascular Diagnostic Procedures; Device
Lead sponsor: Cardiovascular Associates of the Delaware Valley; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more

Conditions: Coronary Heart Disease
Interventions: isolation of endothelial cells precursors in blood; Other
Lead sponsor: Tufts University; Other
Eligibility: 30 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Cardiovascular Diseases
Interventions: Ultravist 370Mg I/Ml Solution for Injection; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Core Binding Factor Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 61 more

Conditions: Coronary Artery Disease
Interventions: treatment with the Azurion system with Xres5, Azurion with Clairy IQ; Device · Other
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • New York, New York

Conditions: Heart Transplant Rejection
Interventions: Standard of Care; Other
Lead sponsor: CareDx; Industry
Eligibility: 15 Years and older
Enrollment: 2,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 67
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Coronary Artery Disease
Interventions: 64 Channel VCT; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Spinal Diseases, Spinal Metastases, Spinal Tumors
Interventions: Melphalan (intra-arterial infusion); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Questionnaire Administration, Selvigaltin; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more

Conditions: Knee Osteoarthritis, Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Interventions: Genicular Artery Embolization, Lipiodol, Simple angiogram; Procedure · Device
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions: Azacitidine, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab, Venetoclax; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 29
States / cities: Greenwich, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 23 more

Conditions: Ischemia
Interventions: CT and stress test; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Overland Park, Kansas • New York, New York • Columbus, Ohio + 2 more

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metabolic Syndrome
Interventions: aged garlic extract, placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 40 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Torrance, California

Conditions: Coronary Artery Disease
Interventions: Coronary MR Angiography (CMRA); Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
Interventions: Swept-Source (SS) OCT Angiography, Spectral-Domain (SD) OCT Angiography, Fundus Imaging, Axial Length Measurement Device; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chest Pain
Interventions: CCTA (coronary computed tomography angiography), Control section; Procedure · Other
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Artery Disease
Interventions: regadenoson and atropine; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cerebral Aneurysms
Interventions: Contour Neurovascular System Treatment Attempt; Device
Lead sponsor: Cerus Endovascular, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Park Ridge, Illinois • Kansas City, Kansas • Buffalo, New York + 5 more

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Prostate Artery Embolization; Device
Lead sponsor: Northwestern University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Breathing-Maneuver-Induced Myocardial Oxygenation Reserve Validated by FFR (B-MORE)

Mynx M5 One Hour Ambulation Study

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Endothelial Cell Gene Networks of CVD

VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

RADIQAL Study (Radiation Dose and Image Quality Trial)

Surveillance HeartCare® Outcomes Registry

A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain

Intra-arterial Chemotherapy for Spinal Metastases

Prevention of Serious Adverse Events Following Angiography

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Effect of Aged Garlic Extract on Atherosclerosis

Identification of Adverse Plaque Characteristics by Coronary MR Angiography

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Coronary Computed Tomography (CT) Angiography Versus Standard Therapy in the Emergency Room

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres